
Opinion|Videos|June 21, 2024
AUA 2024: Outlining BOND-003 Data for NMIBC Therapy
Author(s)Gary Steinberg, MD, FACS
Expert urologist reviews the BOND-003 study, discussing its design, interim outcomes, safety and efficacy data, and the potential for cretostimogene grenadenorepvec to provide a durable response in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Episodes in this series

Video content above is prompted by the following question(s):
- Focusing on the BOND-003 study, please review the study design, key interim outcomes, and safety and efficacy data.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Unmet needs and emerging solutions in MRI-guided prostate cancer care
2
HHS requests testosterone therapy label updates, citing new safety data
3
Microbial dysbiosis may predict response to CBM588 in mRCC
4
Eugene Pietzak, MD, on pembrolizumab plus BCG for BCG-naïve “very high risk” T1 NMIBC
5












